Literature DB >> 25290628

Processing of viral antigens and presentation to class II-restricted T cells.

K H Mills1.   

Abstract

Some antigens require intracellular processing by antigen presenting cells before being presented to T cells in conjunction with surface major histocompatibility complex antigens. The whole mechanism of these processing events is not known and in this article, Kingston Mills puts forward arguments for alternative routes of antigen processing, with particular reference to recognition of viral proteins by class II-restricted T-cell clones.
Copyright © 1986. Published by Elsevier B.V.

Year:  1986        PMID: 25290628     DOI: 10.1016/0167-5699(86)90006-X

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  5 in total

Review 1.  Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus.

Authors:  C J Hackett; L C Eisenlohr
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 2.  Immunoregulatory T cell subsets and T cell activation in rheumatoid arthritis. A need for analysis on the clonal and molecular level.

Authors:  A Quayle; J Kjeldsen-Kragh; O Førre; K Waalen; M Sioud; C Kalvenes; J B Natvig
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  Recognition of influenza virus proteins by cytotoxic T lymphocytes.

Authors:  A R Townsend
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

4.  Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138.

Authors:  R Dardari; W Hinderer; D Lang; A Benider; B El Gueddari; I Joab; A Benslimane; M Khyatti
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Suppression of humoral immune response against herpes simplex virus induced by defective strains, ts- and TK- mutants.

Authors:  B Metzger; J Podlech; S Müller; D Falke
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.